Two Sigma Securities’s Rein Therapeutics RNTX Stock Holding History

Two Sigma Securities’s Portfolio RNTX Stock Details RNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-31,713	Closed	-$41.2K	–	2525
2026 Q1	$41.2K	Buy	31,713 +14,459	+84%	+$17.9K	﹤0.01%	1289
2025 Q4	$20K	Buy	+17,254	New	+$23.8K	﹤0.01%	1182
2025 Q2	–	Sell	-16,271	Closed	-$28.8K	–	2222
2025 Q1	$28.8K	Buy	+16,271	New	+$34.1K	﹤0.01%	1049
2022 Q3	–	Sell	-3,754	Closed	-$20K	–	3207
2022 Q2	$20K	Buy	+3,754	New	+$34.5K	﹤0.01%	1959
2022 Q1	–	Sell	-1,733	Closed	-$20K	–	2598
2021 Q4	$20K	Buy	1,733 +590	+52%	+$9.12K	﹤0.01%	1406
2021 Q3	$23K	Buy	+1,143	New	+$25K	﹤0.01%	1453
2019 Q1	–	Sell	-510	Closed	-$9K	–	2548
2018 Q4	$9K	Buy	+510	New	+$20.5K	﹤0.01%	2026

Other funds holding RNTX

Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return

CCC

Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BCM

BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return

Senvest Management New York $3.41B AUM 66.27% 1-Year Est. Return

Two Sigma Securities's RNTX Position: Q2 2026 in Review

Two Sigma Securities sold out of Rein Therapeutics (RNTX) in Q2 2026, closing a stake of 31,713 shares — an estimated $41.2K sold.

Two Sigma Securities first reported a position in RNTX in Q4 2018 and held it in 7 quarters. The position peaked at $41.2K in Q1 2026. 60 funds tracked by Wall St. Rank hold RNTX as of Q2 2026.

Two Sigma Securities reported no remaining Rein Therapeutics position as of Q2 2026 after selling out during the quarter.
Two Sigma Securities sold 31,713 Rein Therapeutics shares in Q2 2026, an estimated $41.2K.
Two Sigma Securities first reported a position in Rein Therapeutics in Q4 2018 and held it in 7 quarters.
Two Sigma Securities's Rein Therapeutics position peaked at $41.2K in Q1 2026.
60 funds tracked by Wall St. Rank held Rein Therapeutics as of Q2 2026.

Based on Two Sigma Securities's 13F filing for Q2 2026, filed 14 Aug 2026.